Report post
The FDA has approved a new Alzheimer's drug from Eli Lilly, sparking interest in investing in drug companies awaiting FDA approval. Grail's CEO Bob Ragusa predicts that their multi-cancer test will be the first FDA-approved. Meanwhile, Bluebird's stock surged after the FDA approved its gene therapy drug. These approvals highlight the significance of FDA decisions in shaping the future of the pharmaceutical industry and providing investment opportunities.

The World's Leading Crypto Trading Platform

Get my welcome gifts